CINCINNATI, Nov. 14 /PRNewswire-FirstCall/ -- Kendle , a leading global full-service clinical research organization, today announced the appointment of Sylva H. Collins, PhD, as Vice President, Global Biometrics. Dr. Collins will oversee Kendle’s global Biometrics services, which include Clinical Data Management, Biostatistics and Scientific Programming. Kendle provides these services on a stand-alone basis and as part of full-service Phase I-IV clinical development programs for customers worldwide, among whom are many of the world’s largest biopharmaceutical organizations. In addition to her scientific and management expertise, Dr. Collins is a recognized thought leader in the Electronic Data Capture (EDC) field.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
“We are extremely pleased to welcome Dr. Collins to Kendle. Her forward thinking and proven leadership will keep Kendle’s Biometrics services at the forefront of the industry,” said Christopher Bergen, President and Chief Operating Officer. “Her nearly three decades of experience in drug development and her extensive EDC experience will be significant assets as we continue to execute against our ‘Kendle 500' global growth strategy.”
As Vice President, Global Biometrics, Dr. Collins will provide leadership for Kendle’s Biometrics business, which includes data centers in the United States, Europe, Australia and Mexico staffed by more than 500 associates. She will serve on the company’s Management Committee and will be based out of Kendle’s world headquarters in Cincinnati.
Dr. Collins joins Kendle from Novartis Corporation, where she served most recently as Vice President, Global Advanced Clinical Systems, and Vice President, Global Electronic Data Management. In these positions, she implemented and led the global data management operations for more than 400 EDC studies involving approximately 130,000 patients and 16,000 investigator sites on six continents.
About Kendle
Kendle International Inc. is among the world’s leading global clinical research organizations and is the fourth-largest provider of Phase II-IV clinical development services worldwide. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. With the expertise of our 3,000 associates worldwide, Kendle has conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. Additional information and investor kits are available upon request from Kendle, 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202 or from the Company’s Web site at http://www.kendle.com.
Photo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comKendle International Inc.
CONTACT: Investors, Buzz Brenkert, +1-513-345-1525, or Media, Lori Dorer,+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/
